ADC Conjugation Capabilities | Key Technical Questions Answered
Dear Partners,
In ADC development, conjugation is a key step that connects payloads with biologics and has a direct impact on product quality, consistency, and scalability.
With a long-standing focus on conjugation, ChemExpress has established a mature platform and process capabilities, supporting programs across a broad range of conjugation technologies. Here, we address several key questions commonly raised by our partners.
Q: What experience does ChemExpress have in ADC conjugation?
A: ChemExpress has over a decade of experience in conjugation, supporting multiple conjugated drug programs. Our team integrates expertise in antibody production and conjugation process development, helping partners advance projects from early development through scale-up.
Q: What conjugation technologies does ChemExpress support?
A: We support a broad range of established conjugation strategies, enabling tailored selection based on specific project needs, including:
• Non-site-specific conjugation (e.g., cysteine- and lysine-based conjugation)
• Site-specific conjugation (e.g., glycan-based and enzymatic conjugation)
Our team works closely with partners to select the most appropriate strategy based on antibody characteristics, payload properties, and development stage—ensuring an optimal balance between product quality and development efficiency.
Q: What capabilities support conjugation process development and scale-up?
A: ChemExpress has established a conjugation process development and optimization platform supporting process development, validation, and scale-up, enabling a consistent transition to ADC drug substance (DS) manufacturing.
Q: What conjugation systems and scales are available?
A: ChemExpress offers a flexible conjugation platform with multiple reactor systems:
• Disposable reactors: 100L, 200L, 500L
• Stainless steel reactor: 100L
• Glass reactors: 5L,20L,50L,100L
The platform supports conjugation at scales of up to 500L, enabling programs across different stages of development.
Q: What is your conjugation capacity and project throughput?
A: Our ADC drug substance (DS) manufacturing capacity offers an annual capacity of approximately 1,500 kg.
We can support up to 5 conjugation projects in parallel, enabling efficient execution across multiple programs.
Q: How do you ensure containment and prevent cross-contamination?
A: ChemExpress has implemented a comprehensive containment strategy:
• Independent HVAC system with full air supply and exhaust to prevent cross contamination
• BIBO system to ensure operator safety
• Dedicated personnel and material flow for each suite
• Negative-pressure environments with isolator-based operations
• Use of single-use consumables and controlled handling of high-potency materials
These measures ensure effective containment, protecting both operator safety and product quality.
Enabling ADC Development Through Conjugation
Conjugation is a critical step in ADC development, directly influencing product quality, consistency, and scalability.
By combining strong small-molecule expertise with a robust conjugation platform, ChemExpress helps partners advance ADC programs with confidence, delivering reliable and scalable solutions.
For further technical discussion, please contact us at [email protected]。
| • | The Rise of China in ADC Development |
| • | AACR 2025 Preview : Rising Momentum for Dual-Payload ADCs |
| • | Bispecific ADCs: Making 1+1>2 |
| • | China's ADC/XDC Pipeline Fuels Global Breakthroughs |